A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA) AURIGA
Verified

What's the purpose of this trial?

The purpose of this clinical trial is to compare the use of an investigational medicine and lenalidomide vs. lenalidomide alone as maintenance in patients with newly diagnosed multiple myeloma who are minimal residual disease positive after an autologous stem cell transplant.

This trial is currently open and accepting patients.

What's being studied?

  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Lenalidomide is an immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.

What will happen during the trial?

Participants in this study will be randomly assigned to one of two groups (also called arms). Participants in Arm A will receive daratumumab and lenalidomide, while participants in Arm B will receive lenalidomide alone.

Participants in either arm will receive their therapies in 28 day cycles, and may receive up to 36 cycles as long as their myeloma doesn’t get worse or they don’t experience bad side effects.

ARM A

  • Participants will receive daratumumab by a subcutaneous injection weekly during cycles 1 and 2, every two weeks during cycles 3-6, and every four weeks from cycle 7 onwards.
  • Participants will receive lenalidomide by mouth daily. After three cycles, if lenalidomide is well tolerated, the dose may be increased at the discretion at the study doctor.

ARM B

  • Participants will receive lenalidomide by mouth daily. After three cycles, if lenalidomide is well tolerated, the dose may be increased at the discretion at the study doctor.
See if you qualify

Additional Trial Information

Phase 3

Enrollment: 214 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

I'm Interested

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Patient must have newly diagnosed multiple myeloma
  • Patient must have received at least 4 cycles of induction therapy
  • Patient must have had an autologous stem cell transplant within one year of beginning of induction therapy
  • Patient must have minimal residual disease (MRD) as defined by Adaptive Biotechnologies’ NGS-based (MRD) assay
  • Patient must have not had prior treatment with daratumumab or any other anti-CD-38 therapies
  • Patient must not have had radiation therapy within 14 days of joining the study
  • Patient must not have evidence of central nervous system myeloma involvement

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Alabama

UAB Comprehensive Cancer Center University of Alabama at Birmingham

Birmingham, AL

Open and Accepting

Arizona

Arizona Oncology Associates

Glendale, AZ

Open and Accepting

Cancer Treatment Centers of America Western Regional Medical Center

Goodyear, AZ

Not Yet Accepting

California

UCSF Helen Diller Comprehensive Cancer Center University of California San Francisco

San Francisco, CA

Open and Accepting

Moores Cancer Center UC San Diego Health

La Jolla, CA

Open and Accepting

UCLA Jonsson Comprehensive Cancer Center University of California Los Angeles

Los Angeles, CA

Open and Accepting

Colorado

Colorado Blood Cancer Institute Presbyterian/St. Luke's Medical Center (HealthONE)

Denver, CO

Open and Accepting

Rocky Mountain Cancer Centers Denver - Midtown

Denver, CO

Open and Accepting

University of Colorado Health Poudre Valley Hospital

Fort Collins, CO

Open and Accepting

Connecticut

Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Open and Accepting

Florida

Cancer Specialists of North Florida Southpoint

Jacksonville, FL

Open and Accepting

Sylvester Comprehensive Cancer Center University of Miami Health System

Miami, FL

Open and Accepting

Miami Cancer Institute Baptist Health South Florida

Miami, FL

Open and Accepting

Moffitt Cancer Center Magnolia Campus

Tampa, FL

Open and Accepting

Cleveland Clinic Florida

Weston, FL

Open and Accepting

Illinois

Illinois Cancer Specialists

Niles, IL

Open and Accepting

Cancer Treatment Centers of America Midwestern Regional Medical Center

Zion, IL

Not Yet Accepting

Indiana

Fort Wayne Medical Oncology and Hematology Fort Wayne North Office

Fort Wayne, IN

Open and Accepting

Blood and Marrow Transplantation Franciscan Health

Indianapolis, IN

Open and Accepting

Kansas

University of Kansas Cancer Center

Kansas City, KS

Open and Accepting

Louisiana

Ochsner Medical Center

Jefferson, LA

Open and Accepting

Maryland

University of Maryland Medical Center Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, MD

Open and Accepting

Massachusetts

Beth Israel Deaconess Medical Center

Boston, MA

Open and Accepting

Michigan

Henry Ford Hospital

Detroit, MI

Open and Accepting

Cancer and Hematology Centers of Western Michigan (Grand Rapids)

Grand Rapids, MI

Open and Accepting

Mississippi

University of Mississippi Medical Center

Jackson, MS

Open and Accepting

Missouri

Sarah Cannon Cancer Center at Research Medical Center

Kansas City, MO

Open and Accepting

New Jersey

Summit Medical Group MD Anderson Cancer Center

Florham Park, NJ

Open and Accepting

Rutgers Cancer Institute of New Jersey Rutgers, The State University of New Jersey

New Brunswick, NJ

Open and Accepting

New York

New York Oncology Hematology

Albany, NY

Open and Accepting

Montefiore Medical Center

Bronx, NY

Open and Accepting

Northwell Health Monter Cancer Center

Lake Success, NY

Open and Accepting

NYU Winthrop Hospital

Mineola, NY

Open and Accepting

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

New York, NY

Open and Accepting

Mount Sinai Hospital Tisch Cancer Institute

New York, NY

Open and Accepting

SUNY Upstate Medical University State University of New York

Syracuse, NY

Open and Accepting

North Carolina

UNC Lineberger Comprehensive Cancer Center University of North Carolina

Chapel Hill, NC

Open and Accepting

Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

Winston-Salem, NC

Open and Accepting

Levine Cancer Institute Atrium Health

Charlotte, NC

Open and Accepting

Presbyterian Hospital Novant Health

Charlotte, NC

Open and Accepting

Forsyth Medical Center (Silas Creek) Novant Health

Winston-Salem, NC

Open and Accepting

Ohio

Oncology Hematology Care Inc. (Mercy West)

Cincinnati, OH

Open and Accepting

Oregon

Oregon Health and Science University (OHSU) Knight Cancer Institute

Portland, OR

Open and Accepting

Pennsylvania

Sidney Kimmel Cancer Center Thomas Jefferson University

Philadelphia, PA

Open and Accepting

Fox Chase Cancer Center Temple Health

Philadelphia, PA

Open and Accepting

Hillman Cancer Center University of Pittsburgh Medical Center (UPMC)

Pittsburgh, PA

Open and Accepting

Allegheny Health Network (West Penn)

Pittsburgh, PA

Open and Accepting

Reading Hospital and Medical Center

Reading, PA

Open and Accepting

South Carolina

Prisma Health Greenville Memorial Hospital

Greenville, SC

Open and Accepting

Prisma Health Spartanburg

Spartanburg, SC

Open and Accepting

Tennessee

Baptist Cancer Center Memphis

Mempis, TN

Open and Accepting

Sarah Cannon TriStar Centennial Medical Center

Nashville, TN

Open and Accepting

Texas

Texas Oncology Austin Midtown

Austin, TX

Open and Accepting

The University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center

Dallas, TX

Open and Accepting

Texas Oncology (Dallas)

Dallas, TX

Open and Accepting

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

UT Health Science Center Cancer Therapy and Research Center

San Antonio, TX

Not Yet Accepting

Texas Oncology

Tyler, TX

Open and Accepting

Utah

Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Open and Accepting

Virginia

Virginia Cancer Specialists

Fairfax, VA

Open and Accepting

UVA Cancer Center University of Virginia Health System

Charlottesville, VA

Open and Accepting

Virginia Oncology Associates Norfolk (Lake Wright)

Norfolk, VA

Open and Accepting

Washington

University of Washington School of Medicine

Seattle, WA

Open and Accepting

VA Puget Sound Health Care System

Seattle, WA

Not Yet Accepting

Cancer Care Northwest (Sherman)

Spokane, WA

Open and Accepting

Washington, D.C.

MedStar Georgetown University Hospital

Washington, DC

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Janssen Research & Development to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors